NCT06582342 Is the 3D-PANC MSP Model Superior to CT for Assessing Response to Neoadjuvant Treatment in PCA Patients?
| NCT ID | NCT06582342 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fundación para la Investigación del Hospital Clínico de Valencia |
| Condition | Adenocarcinoma of the Pancreas |
| Study Type | OBSERVATIONAL |
| Enrollment | 70 participants |
| Start Date | 2024-03-21 |
| Primary Completion | 2025-12-21 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 70 participants in total. It began in 2024-03-21 with a primary completion date of 2025-12-21.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Prospective multicenter study in which all patients with borderline or locally advanced pancreatic adenocarcioma undergoing neoadjuvant chemotherapy and surgical exploration with curative intent will be included for one year. Preoperative images by traditional CT and 3D-MSP technology will be evaluated, comparing the accuracy variables (sensitivity, specificity, predictive values, area under the curve, concordance index) of both techniques with the gold standard (results of surgery and histopathological analysis).
Eligibility Criteria
Inclusion Criteria: \- Patients with a diagnosis of borderline or locally advanced PAC of the head of the pancreas, as defined by the National Comprehensive Cancer Network (NCCN), who have received neoadjuvant treatment and who undergo surgical exploration with resective intent. Exclusion Criteria: * Patients younger than 18 years of age. * Patients under 18 years of age. * Disease progression during neoadjuvant treatment. * No preoperative CT scan. * Refusal to participate in the study.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06582342 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Adenocarcinoma of the Pancreas. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06582342 currently recruiting?
Yes, NCT06582342 is actively recruiting participants. Contact the research team at dorcaratto.dimitri@gmail.com for enrollment information.
Where is the NCT06582342 trial being conducted?
This trial is being conducted at Alicante, Spain, Badajoz, Spain, Barcelona, Spain, Barcelona, Spain and 11 additional locations.
Who is sponsoring the NCT06582342 clinical trial?
NCT06582342 is sponsored by Fundación para la Investigación del Hospital Clínico de Valencia. The trial plans to enroll 70 participants.